C4X Discovery - Discovery partnership with GTN Ltd.
C4XD enters discovery partnership with state-of-the-art artificial intelligence company, GTN Ltd.
Partnership to maximise insights from shape-based chemistry and generate novel drug candidates in neurodegeneration
Artificial Intelligence is expected to revolutionise the drug discovery industry. GTN is at the forefront of the field, using deep-learning techniques and quantum physics to simulate, filter and search for molecules that are hidden from traditional technologies. However, over-simplistic representation of molecules is a key challenge for the application of artificial intelligence to problems of medicinal chemistry, resulting in suboptimal property prediction and thus results. In order to address this "representation problem", C4XD, using its conformational analysis platform Conformetrix, will provide GTN with world-leading molecular descriptors for use in its in-silico discovery platform. By combining both technologies, the collaboration will aim to unlock new areas of chemical space and identify novel small molecules.
This discovery partnership adds another high value programme to C4XD's portfolio. It represents continued progress against C4XD's strategy of accessing cutting-edge, high impact technologies through productive partnerships that will accelerate growth of its diversified portfolio of commercially attractive assets.
For further information, please contact:
Noor Shaker, Chief Executive Officer +44 (0)7742 213 881
Freddy Crossley, Emma Earl (Corporate Finance)
James Stearns (Corporate Broking)
Mary-Jane Elliott, Chris Gardner, Matthew Neal +44 (0)203 709 5700
About C4X Discovery
C4X Discovery aims to become the world's most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting a range of high value therapeutic areas. The company's goal is to drive returns through early-stage revenue-generating deals with the pharmaceutical industry.
C4X Discovery has a state-of-the-art suite of proprietary technologies across the drug discovery process. The company's innovative DNA-based target identification platform (Taxonomy3®) utilises human genetic datasets to identify novel patient-specific targets leading to greater discovery productivity and increased probability of clinical success. This is complemented by C4XD's novel drug design platform which comprises two innovative chemistry technologies, Conformetrix and Molplex, that combine 4D molecular shape analyses (based on experimental data) with best-in-class computational chemistry. This provides new and unprecedented insight into the behaviour of drug molecules, enabling the production of potent selective compounds faster and more cost effectively than the industry standard.
C4X Discovery is advancing its in-house pipeline that is primarily focused on the high value therapeutic areas of inflammation, neurodegeneration and cancer (including immuno-oncology) with a number of new drug candidates identified and further progress made towards the pre-clinical licensing discussions. In selecting new targets and executing new drug discovery programmes, C4X Discovery focuses on high-value disease areas that are the subject of significant licensing activity and will continue to also maximise value from opportunistic areas such as addiction and diabetes. The Company recently signed a licensing agreement with Indivior for a pre-clinical addiction programme worth up to
The Company was founded as a spin-out from the
GTN's mission is to be the leader in the discovery of high-quality, novel drug candidates. We are helping pharmaceutical companies accelerate drug discovery and do it more efficiently at a fraction of the cost through our proprietary technology. We are building the software technology to efficiently access the full drug-like space, i.e. 10^60, and to more accurately predict chemical activities. We do this through our advanced technology to simulate, evaluate and search for highly effective small molecule drug candidates. Our patent-pending technology, Generative Tensorial Networks, combines ideas from machine learning and quantum physics in order to provide the most accurate representation of chemicals for predicting ADMET, binding affinity and physchem properties, as well as the most advanced technology for discovery of completely novel compounds.
GTN received the CogX UK Rising Star award for Outstanding Achievement in Machine Learning handed to the CEO by the British Prime Minister and was recently featured in
This announcement contains inside information for the purposes of Article 7 of Regulatory (EU) No596/2014
This information is provided by RNS, the news service of the
Quick facts: C4X Discovery Holdings PLC
Market Cap: £18.83 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE